Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates
Portfolio Pulse from
Trevi Therapeutics reported positive results from its Phase 2a RIVER trial for Haduvio in treating refractory chronic cough and idiopathic pulmonary fibrosis. The company completed enrollment for the Phase 2b CORAL trial and expects results in Q2 2025. Trevi ended 2024 with $107.6 million in cash, providing a runway into the second half of 2026.
March 18, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Trevi Therapeutics announced positive Phase 2a trial results for Haduvio, showing benefits in treating refractory chronic cough and idiopathic pulmonary fibrosis. The company completed enrollment for the Phase 2b CORAL trial, with results expected in Q2 2025. Trevi has a strong cash position, extending its runway into 2026.
The positive trial results for Haduvio in treating RCC and IPF are significant as they position Trevi as a leader in this therapeutic area. The completion of enrollment for the Phase 2b trial and a strong cash position further support the company's growth prospects, likely boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100